Scientists test Cancer-Killing virus in patients with Tough-to-Treat breast cancer
NCT ID NCT05081492
Summary
This is a first-in-human, early-stage safety study testing a new type of cancer treatment called an oncolytic virus. The virus, called CF33-hNIS-antiPDL1, is designed to be injected directly into tumors to infect and break down cancer cells, while also potentially helping the patient's own immune system fight the disease. The trial is enrolling a small group of adults with metastatic triple-negative breast cancer that has spread and has not responded to at least two prior treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.